Nasdaq

Exagen Inc. Celebrates Milestone of 1,000,000 AVISE CTD Tests Completed for Autoimmune Diagnostics

Exagen Inc. has reached a major milestone by completing its 1,000,000th AVISE CTD test, a diagnostic tool for autoimmune and connective tissue diseases. This achievement highlights the company’s ...
Morningstar

Autoimmune Disease Testing Market to Reach USD 8.13 Billion by 2035 With CAGR 5.1%

NEWARK, DELAWARE / ACCESS Newswire / February 26, 2026 / The global autoimmune disease testing market is witnessing steady expansion as healthcare systems intensify focus on early diagnosis and ...
FierceBiotech

Selventa Developing Powerful New Class of Multi-omic Based Diagnostic Test for Autoimmune Disease and Cancer

Selventa today announced that it is developing a powerful new class of diagnostic test that will accelerate the implementation of personalized healthcare. Systems Diagnostics, or SysDx™, will be a ...
Seeking Alpha

Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics

CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chief ...
Nasdaq

Exagen Inc. Appoints Dr. Michael Mahler as Chief Scientific Officer to Enhance Autoimmune Diagnostic Innovations

Exagen Inc. has appointed Dr. Michael Mahler as Chief Scientific Officer, recognizing his extensive expertise in immunology and autoimmune research. Dr. Mahler earned his Ph.D. from the University of ...